BOSTON, MA—David J. Dykeman, co-chair of global law firm Greenberg Traurig, LLP’s global Life Sciences & Medical Technology Practice and co-managing shareholder of the firm’s Boston office, spoke on a panel titled “Ownership and Inventorship 2.0: Common and Contemporary IP Due Diligence Landmines for the Life Sciences,” Nov. 15 at the American Conference Institute (ACI) 5th Annual Summit on Life Sciences Intellectual Property (IP) Due Diligence.
The panel discussed the implications for life sciences companies employing artificial intelligence (AI) technologies, unique due diligence strategies for life sciences IP assets involving AI, how to determine inventorship and ownership with multiple inventors, assessing the risk of litigation, analyzing the target company’s policies, and who owns data.
A registered patent attorney with 25 years of experience in patent and IP law, Dykeman focuses his practice on securing worldwide IP protection and related business strategy for high tech clients, with particular experience in life sciences, medical devices, robotics, materials, and information technology. Dykeman provides strategic patent portfolio development and IP advice for clients, including major research institutions, multinational corporations, and early-stage companies. He also performs patent due diligence to assess patent portfolios for venture capital investment, mergers and acquisitions, and licensing opportunities.
The post Greenberg Traurig’s David J. Dykeman Speaks at ACI Summit on Life Sciences IP Due Diligence appeared first on Attorney at Law Magazine.
